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Abstract 
Human Chorionic Gonadotropin (hCG) has recently experi-
enced a resurgence in popular media. Late night television 
commercials and Internet advertisements have suggested 
that it is an essential, unequivocal means to losing weight 
fast. ls hCG really a miracle cure to help patients shed un-
wanted pounds? In 1954, A.T.W. Simeons claimed that hCG 
impacts weight loss by decreasing hunger, increasing fat re-
distribution, and increasing overall mood. Knowing that 
weight 1oss cannot be directly attributed to hCG use, Simeons 
developed a very low calorie diet (VLCD) to which the suc-
cess of the therapy can be attributed. He saw hCG as a means 
to an end. Following a VLCD is nearly impossible without a 
little push, and according to Simeons, this push could be hCG. 
This increase in mood is an essential reagent to following a 
low calorie, thus low-energy diet, and therefore is necessary 
for the product of weight loss. Combination therapy of hCG 
and diet has been studied using multiple dosage forms, but 
no definitive answer has been found. 
Introduction 
Human Chorionic Gonadotropin (hCG) is a glycoprotein hor-
mone normally secreted by trophoblastic cells of the pla-
centa during pregnancy. It was first discovered in the urine 
of pregnant women by Ascheim and Zodek in 1927 and has 
since been widely studied and used in the treatment of infer-
tility.1.2 More recently, hCG has received significant media 
attention regarding its use in weight management in obese 
patients. Despite the positive attention the diet may be get-
ting, available studies show conflicting results and inconsis-
tencies in administration route, dosing, and methods for 
measuring weight loss. hCG has also been evaluated for po-
tential use in the treatment of Kaposi sarcoma, asthma, psy-
choses, osteopenia, and glaucoma.1 
Simeons' Therapy 
The use of hCG in managing body weight is derived from its 
use as a treatment for Frohlich's syndrome, an endocrine 
disorder observed in young boys, which is characterized by 
tumors of the hypothalamus and pituitary as well as exces-
sive fat accumulation.3,4 In 1954, Dr. A.T.W Simeons theo-
rized that hCG might play a role in fat metabolism and could 
potentially stimulate similar weight loss effects in obese indi-
viduals. He proposed that low doses of hCG combined with a 
VLCD would be an effective means of losing weight and be-
gan testing the theory.3 
According to Simeons, hCG liberates fat stores from the waist 
and hips.1 By putting this fat in motion, hCG makes it more 
available for metabolism during the period of low caloric 
intake. With an increased energy source available, patients 
should be able to follow a highly restrictive diet without ex-
periencing overwhelming feelings of hunger or weakness.3.s 
In this way, hCG does not directly stimulate weight loss, but 
rather helps combat the negative side effects associated with 
dieting such as compulsive hunger and lack of energy, which 
likely improves patient compliance with the VLCD. On aver-
age, it was observed that between 250 and 600 g of weight 
were lost daily without a negative impact on energy. In fact, 
when patients were blindly administered saline in place of 
the hCG injection, weight loss continued, but patients com-
plained of weakness, dizziness, and hunger before eventually 
straying from the strict diet and regaining weight.3.6 
In 1974, Simeons compiled a comprehensive diet plan in his 
book, Pounds and Inches: A New Approach to Obesity. His diet 
calls for daily 125 IU injections of hCG combined with a 500 
Kcal/ day diet consisting of lean meat, leafy vegetables, and 
fruit.7 Injections begin three days prior to dieting and cease 
three days before the last scheduled day of the 
diet. Additionally, throughout the two days preceding the 
third injection, patients must consume as much high-fat food 
as possible. The low 500 Kcal/day diet begins after the third 
injection.7 Simeons argues that this initial binge period is 
necessary to build up the body's fat reserves, which will pro-
vide an energy source throughout the diet. Any gain in 
weight during this period should be temporary and will be 
lost quickly when the low calorie diet begins. Furthermore, 
patients must adhere strictly to the 500 calorie allowance 
during the diet and up to three days after the final hCG injec-
tion.6·7 lf hCG is present in the body, Simeons warns that 
even a small increase in caloric intake is predicted to pro-
duce a disproportionately large gain in weightNThe dura-
tion of the diet is dependent upon the individual weight loss 
goals of the patient. For weight loss of 15 pounds or less, 
Simeons recommends a diet consisting of 26 days (23 injec-
tion days plus three days post-injection).7 For weight loss 
goals greater than 15 pounds, the diet may be extended to 
include 40 injections. However, one course of treatment is 
not to exceed 40 injections or a weight loss greater than 34 
pounds, as the body may become adapted to the effects of 
hCG and normal appetite may returnPif necessary, the regi-
men may be repeated several times for further weight loss, 
but patients must abstain from the diet for a period of at 
least six weeks before beginning an additional course of ther-
apy. After completion of the second course, the interval 
should then become progressively longer between each 
repetition. Through multiple courses of treatment, Simeons 
argues that a morbidly obese patient could lose 100 pounds 
ormore.7 
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Literature Review 
A meta-analyses performed by Lijesen, et al. in 1995, con-
cluded that there are more studies reporting that hCG is not 
effective for weight loss compared to those supporting hCG's 
efficacy in weight loss. In fact, of 24 trials that were analyzed 
via computer software, only 12 controlled trials scored above 
50 points on a 100-point system measuring the quality of 
methodolgy.2 Of these 12 studies, only one, the W.L. Asher 
study performed in 1973, found hCG to be an effective ad-
junct in weight loss therapy.2.s 
In a double-blind, placebo-controlled study by Asher, 40 fe-
male patients were divided into two groups to assess the 
effects of Simeons' original diet plan with hCG injections ver-
sus his diet plan with adjunct placebo injections in regard to 
amount of weight lost, as well as hunger and mood of the 
study participants. The women were directed to strictly fol-
low the diet plan, starting with three binge days, followed by 
restricted intake of 500-550 kcal/day divided into two meals 
of specific foods, with an emphasis on little to no fat intake 
for the remainder of the study period (>32 days). Patients 
kept daily food journals and met with nurses six days each 
week to receive the injections and to assess mood, hunger, 
and weight Joss. Strict preparations and administration of 
the hCG injections were also followed. At the end of the trial 
period, the hCG group lost significantly more weight, had a 
significantly greater mean weight loss per injection, and lost 
a significantly greater mean percentage of their starting 
weight, as compared to the placebo group. Additionally, the 
percentage of responses indicating "little or no hunger" and 
"feeling good or excellent" was significantly greater in the 
hCG group versus placebo. The stringent diet, daily meetings, 
and strict preparation and administration of the injectable 
drug differentiate this study from most other studies per-
formed on hCG and weight loss, possibly lending to its posi-
tive results. To further support Simeons' theory, the study 
also analyzed four physicians who administered hCG for 
weight loss. Their patients were not required to follow strict 
diet plans, received injections anywhere from three to five 
days each week, and in some cases were even permitted to 
self-administer injections at home. These patients did not 
benefit from casual hCG use verses placebo. Additionally, 
Asher's placebo study group following a strict diet Jost sig-
nificantly more weight than the casual hCG users of the other 
four physicians. This finding shows that benefits of hCG may 
only be realized when used appropriately. It may also explain 
the negative findings against the use of hCG and weight loss 
conducted by studies with less attention given to Simeons' 
original protocoJ.B 
A double-blind, placebo-controlled study was performed by 
M.R. Stein and others in 197 6 to assess the efficacy of hCG in 
weight Joss. Patients were randomized into two groups and 
received either 125 units of hCG or normal saline daily via 
intramuscular injection. In addition to following the VLCD 
outlined above, participants received these injections six 
days a week over a period of 32 days. Although those partici-
pants on hCG experienced a slightly larger decline in weight, 
it was of no statistical significance, nor was the reduction in 
circumference between the two treatment arms. The authors 
concluded that hCG is no more effective than placebo for 
weight reduction, fat redistribution, or hunger declines. Both 
patients on hCG and those on placebo reported headaches, 
constipation, and fatigue, while one patient receiving hCG 
treatment became pregnant following years of infertility 
problems. While this study was well designed, it differs from 
Simeons' original protocol in significant ways. In this study, 
patients began the 500-calorie diet on the same day they be-
gan receiving injections. They also only received injections 
for 32 days, skipping injections every Sunday. These differ-
ences from Simeons' could have led to the differing results. 
This study also centered on mainly Caucasian women, lead-
ing to poor external validity.9 Additional studies in the 1970s 
also found no use for hCG in weight loss therapy and recom-
mended that treatment of obesity with hCG should come to 
an end.10 A resurgence of the issue emerged in another dou-
ble-blind, placebo-controlled trial published by B. Bosch and 
others in 1990, which also studied only female participants.11 
In 2009, shortly after the release of the Lijesen meta-
analysis, D.O. Belluscio conducted a study to determine the 
efficacy of an entirely new dosage form of hCG. Instead of 
administering intramuscular injections daily, researchers 
administered hCG via a sublingual-enteral route. Researchers 
expected the sublingual route to allow quick absorption 
through the venous plexus under the tongue, thus bypassing 
first pass metabolism in the liver. Participants were sepa-
rated into three groups, receiving either placebo, 125 units of 
hCG twice daily, or 250 units of hCG twice daily, while being 
maintained on a VLCD. This study reported results similar to 
those of Simeons'. They found that although all treatment 
arms lost the same amount of weight, those patients receiv-
ing hCG experienced a larger decrease in waistline circumfer-
ence. Researchers also found hCG to improve mood during 
the diet just as Simeons' had initially claimed. However, fur-
ther testing should be done with this new dosage form to 
assess its overall safety and efficacy versus the injectable 
drug and placebo.1 
hCG Disclaimers and Concerns 
As with all dietary supplements, hCG is not regulated by the 
FDA. Efficacy of dietary supplements is not required to be 
proven upon their addition to the market. Due to this limited 
regulation, there is little initiative to perform trials. Very few 
trials have been performed since Simeons' initial discovery of 
hCG's role in weight loss. There has been some speculation as 
to why hCG proved effective in 1954, but not in more modern 
trials. Celeste Robb-Nicholson, editor-in-chief of the Harvard 
Women's Health Watch, stated that the FDA has suggested 
that there is no benefit to hCG therapy for weight Joss.12 
Roger C. Toffle, of the Department of Obstetrics and Gynecol-
ogy at West Virginia University, supported this FDA claim in 
the West Virginia Medical journal, saying hCG is closely re-
lated to Luteinizing Hormone (LH). In fact, it could be this 
similarity that made hCG therapy effective in treating males 
with Frolich's Syndrome. In this special class of patients, hCG 
may have stimulated LH receptors in the testicles, thus in-
creasing testosterone production. This increase in testoster-
one could have led to an indirect effect on obesity and fat 
distribution. Toffle went on to say that the changes in fat me-
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tabolism during pregnancy may be attributed to placental 
growth hormone, not hCG.4 
If hCG does indeed provide no benefit in weight loss, what 
could be responsible for the elevated mood in those individu-
als receiving treatment in the Belluscio trial? This benefit 
could be attributed to the presence of P-endorphin in some 
commercial preparations of hCG. It could be this addition 
that provides the pharmacological activity, not the hCG it-
self.1 These are only a few perspectives and possible theories 
to discredit the efficacy of hCG; more studies need to be per-
formed to assess the validity of these alternate theories. 
hCG Counseling Points 
Pharmacists should be informed about hCG use including 
available dosage forms, which patients to consider for ther-
apy, and potential side effects in order to provide appropri-
ate counseling to patients. Originally, hCG was available only 
as an injection, but the new sublingual dosage form and its 
appeal for those seeking to lose larger amounts of weight 
rapidly has brought hCG therapy back into public attention. 
Many consumers may not be well informed about the ther-
apy and may see it as an easy way to lose weight. Therefore, 
it is important for the pharmacist to remind patients that 
hCG does not necessarily stimulate weight loss, but possibly 
makes dieting more tolerable. Additionally, though hCG is a 
female hormone, it may also be used safely by men without 
compromising their masculinity.? 
Possible side effects associated with its use include increased 
chance of fertility, hypoglycemia, increased uric acid levels or 
gout, and increased libido. Interference with pregnancy test 
results may also result due to the use of hCG.9,11 Although 
hCG in itself appears to have minimal risks and adverse ef-
fects, following a strict VLCD, as seen in Simeons' therapy, 
without proper supervision by a health care professional can 
be dangerous. Therefore, patients should be encouraged to 
consult a doctor before beginning the hCG diet. 
Conclusion 
There has been a lot of hype in the media about the safety 
and efficacy of hCG in weight management. With respect to 
using hCG for obesity, it would be great to give a definite 
"yes" or a definite "no" in regards to its efficacy. However, 
based upon a review of the available literature, a definitive 
conclusion cannot be reached at this time. Available studies 
show conflicting results and inconsistencies in administra-
tion route, dosing, and methods for measuring weight loss. It 
seems that hCG may be considered safe in conjunction with 
diet, as current literature contains no reports of serious risks 
or adverse events associated with the regimen. However, 
controlled, clinical trials are scant. Upon its initial discovery, 
hCG was found to be beneficial in weight loss only when used 
in combination with a VLCD. Patients on a VLCD as seen in 
Simeons' therapy will likely lose weight if they can overcome 
the overwhelming urge to eat In this sense, hCG may be 
beneficial. More controlled, clinical studies should be 
conducted to assess the place of the hCG diet in weight 
management. 
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